Ozempic 25 mg tablet awaits an FDA decision for type 2 diabetes

Novo Nordisk has filed a supplemental application with the U.S. Food and Drug Administration for a new 25 mg tablet strength of Ozempic (semaglutide) for adults with type 2 diabetes, according to a pipeline tracking update from Prime Therapeutics ^[1]. A decision from the FDA is expected sometime in 2026 ^[1]. Right now, Ozempic tablets top out at 9 mg, so a 25 mg version would mark a notable jump in the top oral dose available under the Ozempic name ^[1].

Ozempic is currently sold as an injectable pen in the United States. The tablet form referenced in this filing is a distinct product path that Novo Nordisk has been developing, and the source describes it as a supplemental application specifically for type 2 diabetes rather than for weight management ^[1]. The source does not give the exact filing date, the specific titration schedule proposed for the new strength, or clinical trial data supporting the higher dose ^[1]. Those details are not yet known from the information available.

The source also does not specify whether this tablet is the same semaglutide tablet already sold as Rybelsus, or a separate formulation carrying the Ozempic brand name ^[1]. Rybelsus is the existing oral semaglutide product approved for type 2 diabetes, and it is not addressed in this filing summary. Because the source material is a general pipeline tracker rather than a detailed clinical or regulatory document, it does not include information on potential side effects specific to the 25 mg strength, pricing, or how it would fit alongside existing Ozempic and Rybelsus options ^[1].

Why it matters for patients

For people with type 2 diabetes who currently take oral semaglutide, a higher tablet strength could eventually mean another option if a lower dose is not providing enough blood sugar control. Some patients prefer pills over injections, and expanding the tablet dosing range could offer more flexibility for those patients and their prescribers if the FDA approves the application ^[1].

But the source is clear that this is only a pending filing, not an approval. The FDA has not yet made a decision, and the 2026 timeline is described as an expectation rather than a confirmed date ^[1]. Patients currently on Ozempic injections or existing tablet doses should not expect any near-term change to their prescriptions based on this filing alone, since the review process is still underway.

It is also not yet known from the available source what evidence the FDA will review to decide on the 25 mg strength, including any data on effectiveness or safety at that higher dose. Readers who want to understand how a new strength might affect them should watch for official FDA action, since a supplemental filing does not guarantee approval.

What happens next

The FDA decision on the 25 mg Ozempic tablet is expected sometime in 2026, according to the pipeline update, though no specific month is given ^[1]. Until the FDA acts, the current maximum tablet strength for Ozempic remains 9 mg ^[1]. Further details about the application, including whether it will be approved, modified, or rejected, are expected to become available as the FDA completes its review, though the exact review timeline beyond